Evaluating the 52-week data from the Phase 2b VOYAGE Study of VK2809 in patients with NASH from the 75th Liver Meeting 2024

Executed on:Dec 12, 2024 3:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Penn State

Transplant Hematologist & Assistant Professor Medicine, Gastroenterology & Hepatology at Penn State.
60% clinical research largely focusing on NASH; hepatology group sees >750 patients with NAFLD/NASH a year of which he manages 25%. 
Lectures nationally on NASH and hi research in this field; and familiar with the MGL-3196 36 Week Data and VK2809.

Interview Goal

On this call we will be looking at the final 52-week data from the VOYAGE study to discuss the trial's primary and secondary endpoints and the tolerability and safety of VK2809.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.